Trial site
Dermedic Iwona Zdybska
Lublin, 20-607, PolandEU-13 widening countryNot linked to an institution yet
- 13running trials
- 5closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 23 trials
- Phase 2/32 trials
- Status
- Active, not recruiting8 trials
- Completed4 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Terminated1 trial
- Lead sponsor
- Pfizer4 trials
- Sanofi3 trials
- Incyte Corporation2 trials
- Celldex Therapeutics1 trial
- Celldex Therapeutics Inc.1 trial
- and 7 more
Running trials
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2025-525022-35-00· Phase 3· Hunan Mabgeek Biotech Co. Ltd.· Source
Not yet recruiting
A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata
2026-526355-62-00· Phase 3· Pfizer Inc.· Source
Recruiting
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
NCT07660835· Phase 2· Galderma R&D· Source
Recruiting
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· UCB Biopharma SRL· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811· Phase 3· Incyte Corporation· Source
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711· Phase 3· Pfizer· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211· Phase 3· Incyte Corporation· Source
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· Phase 3· Celldex Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934· Phase 3· Sanofi· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error